Therapy News and Research

RSS

New mathematical model of bone renewal predicts the effects of osteoporosis medications

The model, described today in eLife, may help improve outcomes for patients with postmenopausal osteoporosis and reduce the risks of side effects by helping physicians build more personalized treatment regimes.

9 Aug 2022

Study uncovers how common genetic mutations cause renal cancer

The understanding of the link between common genetic mutations and certain cancers is increasing.

9 Aug 2022

UNH researchers receive $2.8 million NIH grant to develop and test social assistive robots

Researchers at the University of New Hampshire will receive a five-year grant totaling $2.8 million from the National Institutes of Health (NIH) to develop and test social assistive robots to aid in the care of individuals with Alzheimer's disease and related dementia in the comfort of their own homes.

9 Aug 2022

How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants?

Scientists analyzed the differences between SARS-CoV-2 rebound associated with the Omicron BA.2.12.1 and BA.5 sublineages post-Paxlovid therapy in the United States.

9 Aug 2022

How effective is tecovirimat as a treatment against monkeypox?

A new study evaluated the use of tecovirimat for monkeypox treatment during the current outbreak.

9 Aug 2022

Aldosterone may increase risk of kidney failure in patients with chronic kidney disease

A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal today (Tuesday).

8 Aug 2022

Researchers develop a long-acting injectable formulation of the anti-TB drug rifabutin

In 2020, more than 1.5 million people around the world died of tuberculosis, marking the first time in more than a decade that annual TB deaths had increased and demonstrating the global need for better access to treatments.

8 Aug 2022

Exercise program improves physical functioning among older adults with chronic kidney disease

This randomized trial recently published in the American Journal of Kidney Diseases (AJKD) found that a 12- month program of in-center aerobic and resistance exercise program improved physical functioning among adults 55 years and older with CKD stages G3b-4 and a high level of medical comorbidities.

8 Aug 2022

Combination therapy regimen for cystic fibrosis is also beneficial to primary school-aged children

Cystic fibrosis remains an incurable genetic disorder which impairs lung function and significantly reduces life expectancy.

8 Aug 2022

Brain-robot interfaces may help the brain reroute motor pathways damaged during stroke

Brain-robot interfaces - apparatuses where brain activity controls the movements of a robotic device that supports a hand or limb - show promise in rehabilitating paralyzed stroke patients.

8 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

Sperm not affected nine months after COVID-19 mRNA vaccination

A recent study compared the effects of COVID-19 vaccines on male fertility at a median of nine months after receipt of two mRNA vaccine doses.

8 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Researchers examine the incidence of second primary lung cancers using National Lung Screening Trial data

Using data from the National Lung Screening Trial, researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of lung cancer patients and was as high as 8% among patients undergoing surgery for stage IA disease.

8 Aug 2022

The impact of cold agglutinin syndrome on clinical presentations in COVID-19

Researchers presented two cases to highlight the impact of cold agglutinin syndrome on clinical presentations in COVID-19.

8 Aug 2022

Insights into the products and services of Azenta

This interview talks to Andre Kotze about the different services and products available at Azenta.

From Azenta Life Sciences 8 Aug 2022

Terminally exhausted T cells may remain competent for transcription, researchers say

During a battle with cancer, T cells can become exhausted and are no longer able to function properly. The early phase of exhaustion can sometimes be reversed with immunotherapy drugs, but once T cells become too exhausted, it had been thought that this state was irreversible. However, new insights from University of Pittsburgh and UPMC researchers suggest that even the most fatigued T cells can be revived.

8 Aug 2022

Therapy News and Research

New mathematical model of bone renewal predicts the effects of osteoporosis medications

Study uncovers how common genetic mutations cause renal cancer

UNH researchers receive $2.8 million NIH grant to develop and test social assistive robots

How does COVID-19 rebound after Paxlovid treatment differ between the BA.5 and BA.2.12.1 subvariants?

How effective is tecovirimat as a treatment against monkeypox?

Aldosterone may increase risk of kidney failure in patients with chronic kidney disease

Researchers develop a long-acting injectable formulation of the anti-TB drug rifabutin

Exercise program improves physical functioning among older adults with chronic kidney disease

Combination therapy regimen for cystic fibrosis is also beneficial to primary school-aged children

Brain-robot interfaces may help the brain reroute motor pathways damaged during stroke

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Sperm not affected nine months after COVID-19 mRNA vaccination

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

Researchers examine the incidence of second primary lung cancers using National Lung Screening Trial data

The impact of cold agglutinin syndrome on clinical presentations in COVID-19

Insights into the products and services of Azenta

Terminally exhausted T cells may remain competent for transcription, researchers say

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News